tailieunhanh - Cost-effectiveness of first-line immunotherapy combinations with or without chemotherapy for advanced non–small cell lung cancer: A modelling approach

Many studies have explored the cost-effectiveness of immunotherapy versus chemotherapy alone. However, there is paucity of evidence on direct pharmacoeconomic studies related to immunotherapy combinations. |

TÀI LIỆU LIÊN QUAN
TỪ KHÓA LIÊN QUAN